SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ...
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ...
The treatments for both classic and nonclassic congenital adrenal hyperplasia (CAH) include medication, surgery, and psychological support, or a combination of all three. Some people who have CAH, ...
Objective Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is an inherited adrenal steroid synthesis disorder included in Dutch newborn screening (NBS) since 2002. Screening ...
SAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) ...
VALBY, Denmark, June 24, 2025 /PRNewswire/ -- Lundbeck today announces that orphan drug designation has been granted to Lu AG13909 by the US Food and Drug Administration (FDA) on 12 May 2025 and the ...
Credit: Getty Images Researchers conducted the CAHtalyst Pediatric trial to assess the effects of crinecerfont among pediatric patients with congenital adrenal hyperplasia. Compared with placebo, ...
Orlando, Florida — New data add to the evidence supporting use of crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in both adults and children.
As of 2020, 1 in every 20,550 children are screened with Congenital Adrenal Hyperplasia (CAH) through the Expanded Newborn Screening (ENBS). Congenital Adrenal Hyperplasia is a spectrum of disorders ...